Neurodegenerative diseases are characterized by uncontrolled neuronal death leading to a gradual decline in brain functions. In neurological disorders, protein aggregation and misfolding play a key role in disease advancement. Evidence of protein amyloids is the most communal characteristic of neurodegenerative diseases, such as Alzheimer's disease, Parkinson’s disease, Amyotrophic lateral sclerosis, and Huntington's diseases but the specific forms of protein aggregation mechanism remain unclear. Moreover, Prion-like dissemination of several aggregated proteins may trigger the progression of pathology in distinct neurodegenerative diseases. Further investigation into the triggers, facilitators, and aggravators of protein aggregation and propagation is crucial for understanding the pathogenesis of neurodegenerative diseases and developing novel therapeutic approaches. For instance, exploring the mechanisms underlying the cellular release and uptake of protein aggregates is important for searching therapeutic targets. Understanding the role of free extracellular aggregates is critical for finding diagnostic biomarkers and developing antibody or small molecule therapy. On the other hand, early disease diagnosis is crucial as it can provide opportunities for meaningful therapeutic intervention at a stage when the progression of the disease can still be prevented, leading to improved outcomes.
Biomarkers are quantitatively measured signs of normal biological or pathogenic processes that can significantly impact future care and treatment. Moreover, therapeutic advancements and biomarkers identifications are paving the way towards new treatment regimens with the recent technological advances in proteomics, transcriptomics, and metabolomics studies. Furthermore, these studies could offer crucial insights into disease mechanisms, as well as opportunities for the development of novel drugs that can prevent or slow down neurodegeneration.
In this Research Topic, we welcome original contributions and review articles related to all studies that employ a multi-omics strategy to address the critical need for finding novel therapeutic targets, diagnosis of new biomarkers, and drug development studies for neurodegenerative diseases. We welcome both experimental and computational studies with technology including but not limited to:
• GWAS studies on patients samples
• microarray and mRNA studies or in silico mapping on network-based approaches
• molecular dynamics studies on proteins, protein-protein interaction studies, peptide therapeutics.
We consider that this streak of publications will provide a wider platform to showcase the recent advancement in the thrust areas of research in providing further insights into the treatment and prevention of neurological disorders.
Neurodegenerative diseases are characterized by uncontrolled neuronal death leading to a gradual decline in brain functions. In neurological disorders, protein aggregation and misfolding play a key role in disease advancement. Evidence of protein amyloids is the most communal characteristic of neurodegenerative diseases, such as Alzheimer's disease, Parkinson’s disease, Amyotrophic lateral sclerosis, and Huntington's diseases but the specific forms of protein aggregation mechanism remain unclear. Moreover, Prion-like dissemination of several aggregated proteins may trigger the progression of pathology in distinct neurodegenerative diseases. Further investigation into the triggers, facilitators, and aggravators of protein aggregation and propagation is crucial for understanding the pathogenesis of neurodegenerative diseases and developing novel therapeutic approaches. For instance, exploring the mechanisms underlying the cellular release and uptake of protein aggregates is important for searching therapeutic targets. Understanding the role of free extracellular aggregates is critical for finding diagnostic biomarkers and developing antibody or small molecule therapy. On the other hand, early disease diagnosis is crucial as it can provide opportunities for meaningful therapeutic intervention at a stage when the progression of the disease can still be prevented, leading to improved outcomes.
Biomarkers are quantitatively measured signs of normal biological or pathogenic processes that can significantly impact future care and treatment. Moreover, therapeutic advancements and biomarkers identifications are paving the way towards new treatment regimens with the recent technological advances in proteomics, transcriptomics, and metabolomics studies. Furthermore, these studies could offer crucial insights into disease mechanisms, as well as opportunities for the development of novel drugs that can prevent or slow down neurodegeneration.
In this Research Topic, we welcome original contributions and review articles related to all studies that employ a multi-omics strategy to address the critical need for finding novel therapeutic targets, diagnosis of new biomarkers, and drug development studies for neurodegenerative diseases. We welcome both experimental and computational studies with technology including but not limited to:
• GWAS studies on patients samples
• microarray and mRNA studies or in silico mapping on network-based approaches
• molecular dynamics studies on proteins, protein-protein interaction studies, peptide therapeutics.
We consider that this streak of publications will provide a wider platform to showcase the recent advancement in the thrust areas of research in providing further insights into the treatment and prevention of neurological disorders.
